Previous 10 | Next 10 |
Caladrius Biosciences (CLBS) announces that the FDA has authorized its investigational new drug ((IND)) application for the study of CLBS201, a CD34+ cell therapy for the treatment of diabetic kidney disease ((DKD)). “We plan to initiate a phase 1/2 proof-of-concept study of CLBS201 wi...
BASKING RIDGE, N.J., June 22, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today anno...
BASKING RIDGE, N.J., June 17, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today...
Featuring Avalon GloboCare (AVCO), Caladrius Biosciences (CLBS), Celularity, ImmCelz / Creative Medical Technology Holdings (CELZ), ExoProTher, GID BIO, HealthLynked (HLYK), Longeveron (LGVN), Mesoblast (MESO) - Presented by Channelchek and Noble Capital Markets Read More >>
Investor Forum at the World Stem Cell Summit - June 17, 2021 - presented by Channelchek - Featuring Avalon GloboCare, Caladrius Biosciences, CellZ, Celularity, ExoProTher, GID BIO, Longeveron, Medicinal Cells, Inc., Mesoblast Read More >>
BASKING RIDGE, N.J., June 01, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today...
Caladrius Biosciences (CLBS) shares rise over 15% during premarket trading after receiving $1.4M in non-dilutive funding as part of the Technology Business Tax Certificate Transfer Program sponsored by the New Jersey Economic Development Authority ((NJEDA)).The Program enables quali...
Second Sight Medical Products (EYES) +24% on reporting two-year results of its Orion study.Upstart Holdings (UPST) +23% on Q1 results.Minerva Neurosciences (NERV) +23% on Q1 results.fuboTV Inc. (FUBO) +21% on Q1 results.Biomerica (BMRA) +17%.Lucira Health (LHDX) +16% ...
BASKING RIDGE, N.J., May 12, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today annou...
Caladrius Biosciences, Inc. (CLBS) Q1 2021 Results Earnings Conference Call May 06, 2021, 04:30 PM ET Company Participants John Menditto - Vice President, Investor Relations and Corporate Communications David Mazzo - President and Chief Executive Officer James Nisco - Vice President, Finance ...
News, Short Squeeze, Breakout and More Instantly...
Caladrius Biosciences Inc. Company Name:
CLBS Stock Symbol:
NASDAQ Market:
Caladrius Biosciences Inc. Website:
BASKING RIDGE, N.J., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), announced today that, based upon the final vote count certified by the independent inspector of elections for the annual meeting of ...
NEW YORK, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the upcoming Life Sciences Virtual Investor Conference to be held on September 15 th . Individual investors, institutional ...
BASKING RIDGE, N.J., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies designed to treat or reverse disease, today announced tha...